Involvement of dopamine receptors in the antipsychotic profile of(-)eticlopride

Physiology and Behavior

Volumn 61, Issue 4, 1997, Pages 563-567

  Giuliani, Daniela ^a   Ferrari, Francesca ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

( )Eticlopride; Cocaine; DA D2 D3 receptors; Hypermotility; Ketamine; Psychosis; Stereotypy

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; COCAINE; CQP 201403; DOPAMINE RECEPTOR; ETICLOPRIDE; KETAMINE; PRAMIPEXOLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030975310     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-9384(96)00503-3     Document Type: Article

References (37)

1. Baldessarini R. J., Kula N. S., McGrath C. R., Bakthavachalam V., Kebabian J. W., Neumeyer J. L. Isomeric selectivity at dopamine D3 receptors. Eur. J. Pharmacol. 239:1993;269-270.
2. Berger P. A., Elliott G. R., Barchas J. D. Neuroregulators and schizophrenia. Lipton M. A., DiMascio A., Killam K. F. Psychopharmacology: a generation of progress. 1978;1070-1082 Raven Press, New York.
3. 2 receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse. Psychopharmacology. 105:1991;335-339.
4. 3-preferring dopamine agonist. Neurosci. Lett. 196:1995;97-100.
5. Carlsson A. Mechanism of action of neuroleptic drugs. Lipton M. A., DiMascio A., Killam K. F. Psychopharmalogy: a generation of progress. 1978;1057-1070 Raven Press, New York.
6. Costall B., Domeney A. M., Naylor R. J. Stimulation of rat spontaneous locomotion by low doses of haloperidol and (-) sulpiride: importance of animal selection and measurement technique. Eur. J. Pharmacol. 90:1983;307-314.
7. 2-like" agonists. Neuropharmacology. 32:1993;509-510.
8. 3 receptor ligand. Eur. J. Pharmacol. 249:1993;R9-10.
9. De Paulis T., Hall H., Ogren S. O., Wagner A., Stensand B., Csoregh I. Synthesis, crystal structure and anti-dopaminergic properties of eticlopride (FLB 131). Eur. J. Med. Chem. 20:1985;273-279.
10. Elison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Rev. 20:1995;250-267.
11. Ferrari F. Behavioral effects induced in male rats by CQP 201-403 and CQ 32-084, two novel ergot-derivative. Pharmacol. Life Sci. Adv. 9:1990;21-26.
12. 2 receptor agonist-induced behavioural effects in rats. Eur. J. Pharmacol. 250:1993;51-57.
13. 2 dopamine agonist SND 919 in the rat. Life Sci. 55:1994;1155-1162.
14. Ferrari F., Giuliani D. Behavioral effects od the dopamine D3 receptor agonist 7-OH-DPAT in rats. Pharmacol. Res. 31:1995;1-6.
15. 2 receptor antagonist, (-) eticlopride. Pharmacol. Res. 31:1995;261-268.
16. 2 agonist-induced behavioral effects in rats. Pharmacol. Biochem. Behav. 53:1996;525-530.
17. 2 dopamine receptor agonist. Psychopharmacology. 113:1993;172-176.
18. Fielding S., Lal H. Preclinical neuropharmacology of neuroleptics. Fielding S., Lal H. Neuroleptics. 1974;64-65 Futura Press, New York.
19. 2 receptors in the rat brain. Eur. J. Pharmacol. 111:1985;191-199.
20. Irifune M., Shimizu T., Nomoto M. Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacol. Biochem. Behav. 40:1991;399-407.
21. Javitt D. C., Zukin S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatr. 148:1991;1301-1308.
22. Jenner P., Marsden C. D. Substituted benzamide drugs as selective neuroleptic agents. Neuropharmacology. 20:1981;1285-1293.
23. Kalivas P. W., Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse. 5:1990;48-58.
24. Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
25. 3H] eticlopride in the rat brain: evidence for selective labelling of dopamine receptors. Eur. J. Pharmacol. 120:1986;217-226.
26. 3 receptor binding by N-ethylmaleimide and neurotensin. Brain Res. 643:1994;343-348.
27. Lodge D., Johnson K. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol. Ther. 11:1990;81-86.
28. 3 receptor expressed in transfected cell lines. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 266:1994;79-85.
29. Morita T., Hitomi S., Saito S, Fujita T., Uchihashi Y., Kuribara H. Repeated ketamine administration produces upregulationm of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice. Psychopharmacology. 117:1995;396-402.
30. Ogren S. O., Hall H., Kohler C. H., Magnusson O., Florvall L. Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur. J. Pharmacol. 102:1984;459-474.
31. Post R. M., Contel N. R. Human and animal studies of cocaine: implication for development of behavioral pathology. Creese I. Stimulants: Neurochemical, behavioral and clinical perspectives. 1983;69-203 Raven Press, New York.
32. Post R. M., Rose H. Increasing effects of repetitive cocaine administration in the rat. Nature. 260:1976;731-732.
33. Seeman P. Brain dopamine receptors. Pharmacol. Rev. 32:1980;229-313.
34. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
35. Snell L. D., Mueller Z. L., Gannon R. L., Silverman P. B., Johnson K. M. A comparison between classes of drugs having phencyclidine-like behavioral properties on dopamine efflux in vitro and dopamine metabolism in vivo. J. Pharmacol. Exp. Ther. 231:1984;261-269.
36. Taylor D. L., Ho B. T., Fagen J. D. Increased dopamine receptor binding in rat by repeated cocaine injections. Commun. Psychopharmacol. 3:1979;137-142.
37. Trabucchi M., Longoni R., Fresia P., Spano P. F. Sulpiride: a study of the effects on dopamine receptors in rat neostriatum and limbic forebrain. Life Sci. 17:1975;1551-1556.